Nancy Chan
ECOG-ACRIN Cancer Research Group · NYU Langone Health · Rutgers Cancer Institute of New Jersey
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nancy Chan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:58 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07391774 · Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialNational Cancer Institute (NCI) · recruiting · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8 · principal investigator
- N/ANCT06927895 · Breast Cancer Implementation Science Study With Educational InterventionNYU Langone Health · recruiting · Breast Cancer · principal investigator
- Ph2NCT03393845 · Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer PatientsNancy Chan, MD · active not recruiting · Breast Cancer · principal investigator
- Ph1NCT01407562 · Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid TumorsRutgers, The State University of New Jersey · terminated · Unspecified Adult Solid Tumor - Protocol Specific, Breast Cancer - Female · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review and Monitoring SystemP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · fiscal years 2024 to 2026 · $30,243 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT07391774
- Cancer Center AdministrationP30CA072720 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI John Pounardjian · fiscal years 1997 to 2026Named on NCT01407562
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 09:58 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- 205 citationsRCR 6.9
- Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.Ann Oncol · 202085 citationsRCR 3.1
- A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.Invest New Drugs · 202019 citationsRCR 0.6
- Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.Breast Cancer Res Treat · 20216 citationsRCR 0.3
- A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.Cancer Chemother Pharmacol · 20223 citationsRCR 0.2